Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2087913 | 0.75 | TSHR (0.55) | MAPTRECQLSMN1; SMN2TSHRCASP3 | |
| SCHEMBL2807993 | 0.72 | TSHR (0.56) | MAPTRECQLSMN1; SMN2TSHRCASP3 | |
| SCHEMBL7894073 | 0.72 | TSHR (0.59) | MAPTRECQLSMN1; SMN2TSHRCASP3 | |
| SCHEMBL10754225 | 0.71 | CASP3 (0.56) | MAPTRECQLCASP3HTTALDH1A1 | |
| SCHEMBL18668961 | 0.69 | CASP3 (0.53) | CASP3ALDH1A1MEN1PKMKMT2A | |
| SCHEMBL29820192 | 0.69 | CASP3 (0.65) | MAPTCASP3HPGDHTTRPS6KA2 | |
| SCHEMBL8737445 | 0.69 | CASP3 (0.65) | MAPTCASP3HPGDHTTRPS6KA2 | |
| SCHEMBL17151755 | 0.69 | HPGD (0.49) | MAPTRECQLSMN1; SMN2TSHRCASP3 | |
| SCHEMBL18668934 | 0.68 | CA12 (0.55) | TSHRCASP3ALDH1A1MEN1PKM | |
| SCHEMBL10304923 | 0.68 | PTGS1 (0.65) | MAPTRECQLTSHRCASP3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10150764-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2018-12-11 | — | — | US | disclosed |
| EP-3022184-B1 | SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20160194316-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2016-07-07 | — | — | US | disclosed |
| EP-3022184-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015010049-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194316-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | MAPT 4181/4885RECQL 1050/4885SMN1; SMN2 2744/4885 |
| US-10150764-B2 | Substituted benzene compounds | CYP1B1, TP53, VHL | MAPT 4181/4885RECQL 1050/4885SMN1; SMN2 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.